Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.54 |
| ▸ | DDAH1 | O94760 | 4/20 | 0.50 |
| ▸ | NOS2 | P35228 | 6/20 | 0.49 |
| ▸ | NOS1 | P29475 | 6/20 | 0.49 |
| ▸ | NOS3 | P29474 | 5/20 | 0.49 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ARG2 | P78540 | 4/20 | 0.43 |
| ▸ | ARG1 | P05089 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL28092102 | 1.00 | OTC (0.54) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL304861 | 1.00 | OTC (0.54) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL509981 | 1.00 | OTC (0.54) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL28092103 | 1.00 | OTC (0.54) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL7323105 | 1.00 | OTC (0.54) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL5213086 | 1.00 | OTC (0.54) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL508562 | 1.00 | OTC (0.54) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL7104172 | 1.00 | OTC (0.54) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL6437733 | 0.98 | OTC (0.53) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL28870403 | 0.98 | OTC (0.53) | OTCDDAH1NOS2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3064501-A1 | 2-METHYLSULPHANYL-6-NITRO-7-OXO-1, 2, 4-TRIAZOLO [5, 1-C][1, 2, 4]TRIAZINIDE L-ARGININE DIHYDRATE ACTIVE TOWARD WEST NILE VIRUS | Limited Liability Company "Ural Center of Biopharmaceutical Technology" (RU) | 2016-09-07 | — | — | EP | claimed |
| JP-57035548-A | — | — | None | — | — | JP | disclosed |
| CN-116999447-A | Co-amorphous substance of mesalamine and arginine as well as preparation method and application thereof | 山东济世药业有限公司 | 2023-11-07 | — | — | CN | disclosed |
| EP-3064501-B1 | 2-METHYLSULPHANYL-6-NITRO-7-OXO-1, 2, 4-TRIAZOLO [5, 1-C][1, 2, 4]TRIAZINIDE L-ARGININE DIHYDRATE ACTIVE TOWARD WEST NILE VIRUS | LIMITED LIABILITY COMPANY URAL CENTER OF BIOPHARMACEUTICAL TECH (RU) | 2019-08-21 | — | — | EP | disclosed |
| US-9790227-B2 | 2-methylsulphanyl-6-nitro-7-oxo-1, 2, 4-triazolo [5, 1-C] [1, 2, 4] triazinide L-arginine dihydrate active toward west nile virus | LIMITED LIABILITY COMPANY “URAL CENTER OF BIOPHARMACEUTICAL TECHNOLOGY” (RU) | 2017-10-17 | — | — | US | disclosed |
| US-9790227-B2 | 2-methylsulphanyl-6-nitro-7-oxo-1, 2, 4-triazolo [5, 1-C] [1, 2, 4] triazinide L-arginine dihydrate active toward west nile virus | LIMITED LIABILITY COMPANY “URAL CENTER OF BIOPHARMACEUTICAL TECHNOLOGY” (RU) | 2017-10-17 | — | — | US | disclosed |
| US-20160318934-A1 | 2-METHYLSULPHANYL-6-NITRO-7-OXO-1, 2, 4-TRIAZOLO [5, 1-C] [1, 2, 4] TRIAZINIDE L-ARGININE DIHYDRATE ACTIVE TOWARD WEST NILE VIRUS | LIMITED LIABILITY COMPANY "URAL CENTER OF BIOPHARMACEUTICAL TECHNOLOGY" (RU) | 2016-11-03 | — | — | US | disclosed |
| US-20160318934-A1 | 2-METHYLSULPHANYL-6-NITRO-7-OXO-1, 2, 4-TRIAZOLO [5, 1-C] [1, 2, 4] TRIAZINIDE L-ARGININE DIHYDRATE ACTIVE TOWARD WEST NILE VIRUS | LIMITED LIABILITY COMPANY "URAL CENTER OF BIOPHARMACEUTICAL TECHNOLOGY" (RU) | 2016-11-03 | — | — | US | disclosed |
| EP-3064501-A1 | 2-METHYLSULPHANYL-6-NITRO-7-OXO-1, 2, 4-TRIAZOLO [5, 1-C][1, 2, 4]TRIAZINIDE L-ARGININE DIHYDRATE ACTIVE TOWARD WEST NILE VIRUS | Limited Liability Company "Ural Center of Biopharmaceutical Technology" (RU) | 2016-09-07 | — | — | EP | disclosed |
| WO-2015065243-A1 | 2-METHYLSULPHANYL-6-NITRO-7-OXO-1, 2, 4-TRIAZOLO [5, 1-C] [1, 2, 4] TRIAZINIDE L-ARGININE DIHYDRATE ACTIVE TOWARD WEST NILE VIRUS | Общество с ограниченной ответственностью "Уральский центр биофармацевтических технологий" | 2015-05-07 | — | — | WO | disclosed |
| EP-0587121-B1 | Crystalline dihydrate of a cephalosporin dihydrochloride salt and injectable compositions thereof | BRISTOL MYERS SQUIBB CO (US) | 1998-11-11 | — | — | EP | disclosed |
| EP-0714884-A1 | A method for the production of a basic amino acid | Ajinomoto Co., Inc. (JP) | 1996-06-05 | — | — | EP | disclosed |
| EP-0651763-A1 | OLIGOPEPTIDE COLLAGEN DERIVATIVES AND THEIR USE IN SECONDARY CATARACT PREVENTION | LABORATOIRE CHAUVIN SA (FR) | 1995-05-10 | — | — | EP | disclosed |
| US-5401842-A | Antibiotics | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-03-28 | — | — | US | disclosed |
| EP-0587121-A1 | Crystalline dihydrate of a cephalosporin dihydrochloride salt and injectable compositions thereof | Bristol-Myers Squibb Company (US) | 1994-03-16 | — | — | EP | disclosed |
| WO-1994001456-A1 | OLIGOPEPTIDE COLLAGEN DERIVATIVES AND THEIR USE IN SECONDARY CATARACT PREVENTION | LABORATOIRE CHAUVIN (FR) | 1994-01-20 | — | — | WO | disclosed |
| JP-S5735548-A | DRYING METHOD OF AMINO ACID CRYSTAL | AJINOMOTO CO INC | 1982-02-26 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318934-A1 | 2-METHYLSULPHANYL-6-NITRO-7-OXO-1, 2, 4-TRIAZOLO [5, 1-C] [1, 2, 4] TRIAZINIDE L-ARGININE DIHYDRATE ACTIVE TOWARD WEST NILE VIRUS | NOS1, ARG1, NOS2 | OTC 104/4885DDAH1 118/4885NOS2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.